Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR Dealing
Tiziana Life Sciences has disclosed that Gabriele Cerrone, Executive Chairman, acquired 45,000 ordinary shares at 84p each on November 18, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tiziana Life Sciences has disclosed that Gabriele Cerrone, Executive Chairman, acquired 45,000 ordinary shares at 84p each on November 18, 2020. This purchase increased Cerrone's shareholding from 34.029% to 34.052%, just above the 1% threshold under the UK Takeover Code. The acquisition reflects Cerrone's continued confidence in the company's prospects within the biotechnology sector, which focuses on oncology and infectious diseases.
Positive
- Gabriele Cerrone's increased shareholding indicates strong confidence in Tiziana Life Sciences' future.
Negative
- None.
Details
News Market Reaction – TLSA
The recorded move for TLSA in the trading session of this news was -0.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share.
The acquisition takes Mr Cerrone's interests from
| 1. | Details of PDMR / person closely associated | |
| a) | Name | Gabriele Cerrone |
| 2. | Reason for the notification | |
| a) | Position / status | Executive Chairman |
| b) | Initial notification /amendment | Initial notification |
| 3. | Details of the issuer | |
| a) | Name | Tiziana Life Sciences plc |
| b) | LEI | 213800CED47HI8PIOB36 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument | Ordinary Shares of 3p each |
| b) | Identification code of the Financial Instrument | ISIN for Tiziana Life Sciences plc: GB00BKWNZY55 |
| c) | Nature of the transaction | Market Purchase |
| d) | Price(s) and volume(s) | 84p 45,000 |
| f) | Date of the transaction | 18 November 2020 |